English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Oral glucocorticoid therapy is widely used for the treatment of a variety of diseases. Approximately 1% of the population is prescribed oral glucocorticoids, and in the elderly this prevalence rises to 2.5% [1]. The association between glucocorticoid therapy and osteoporosis is well documented and exhibits some characteristic features [2]. Bone loss is particularly rapid in the first few months after initiation of therapy, with a slower rate of loss subsequently [3]. Fracture risk also increases rapidly during the early months of therapy and declines after its cessation [4, 5]. Both cortical and cancellous bone are affected, and there is some reversibility of bone loss after cessation or reduction of therapy [3, 6]. Although the severity of osteoporosis is related to the dose and Osteoporos Int (2008) 19:1247–1250 DOI 10.1007/s00198-008-0670-7

osteoporosis international

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science